Optimization of base editors for the functional correction of SMN2 as a treatment for spinal muscular atrophy

被引:7
|
作者
Alves, Christiano R. R. [1 ,2 ,3 ]
Ha, Leillani L. [1 ,4 ]
Yaworski, Rebecca [5 ,6 ,7 ]
Sutton, Emma R. [5 ,6 ,7 ]
Lazzarotto, Cicera R. [8 ]
Christie, Kathleen A. [1 ,4 ,9 ]
Reilly, Aoife [5 ,6 ,7 ]
Beauvais, Ariane [5 ,6 ,7 ]
Doll, Roman M. [1 ,4 ,10 ,11 ]
de la Cruz, Demitri [12 ,13 ]
Maguire, Casey A. [12 ,13 ]
Swoboda, Kathryn J. [1 ,2 ,3 ]
Tsai, Shengdar Q. [8 ]
Kothary, Rashmi [5 ,6 ,7 ,14 ]
Kleinstiver, Benjamin P. [1 ,4 ,9 ]
机构
[1] Massachusetts Gen Hosp, Ctr Genom Med, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA
[3] Harvard Med Sch, Dept Neurol, Boston, MA 02115 USA
[4] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
[5] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[6] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada
[7] Univ Ottawa, Ctr Neuromuscular Dis, Ottawa, ON, Canada
[8] St Jude Childrens Res Hosp, Dept Hematol, Memphis, TN USA
[9] Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA
[10] Heidelberg Univ, Mol Biosci Canc Biol Program, Heidelberg, Germany
[11] German Canc Res Ctr, Heidelberg, Germany
[12] Massachusetts Gen Hosp, Dept Neurol, Mol Neurogenet Unit, Charlestown, MA USA
[13] Harvard Med Sch, Program Neurosci, Boston, MA USA
[14] Univ Ottawa, Dept Med, Ottawa, ON, Canada
基金
加拿大健康研究院; 美国国家卫生研究院;
关键词
SURVIVAL MOTOR-NEURON; CRISPR-CAS9; NUCLEASES; SPLICING MODIFIER; NATURAL-HISTORY; SHAM CONTROL; GENOMIC DNA; MOUSE MODEL; NUSINERSEN; RISDIPLAM; THERAPY;
D O I
10.1038/s41551-023-01132-z
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Spinal muscular atrophy (SMA) is caused by mutations in SMN1. SMN2 is a paralogous gene with a C center dot G-to-T center dot A transition in exon 7, which causes this exon to be skipped in most SMN2 transcripts, and results in low levels of the protein survival motor neuron (SMN). Here we show, in fibroblasts derived from patients with SMA and in a mouse model of SMA that, irrespective of the mutations in SMN1, adenosine base editors can be optimized to target the SMN2 exon-7 mutation or nearby regulatory elements to restore the normal expression of SMN. After optimizing and testing more than 100 guide RNAs and base editors, and leveraging Cas9 variants with high editing fidelity that are tolerant of different protospacer-adjacent motifs, we achieved the reversion of the exon-7 mutation via an A center dot T-to-G center dot C edit in up to 99% of fibroblasts, with concomitant increases in the levels of the SMN2 exon-7 transcript and of SMN. Targeting the SMN2 exon-7 mutation via base editing or other CRISPR-based methods may provide long-lasting outcomes to patients with SMA.
引用
收藏
页码:118 / +
页数:17
相关论文
共 50 条
  • [41] An extended inhibitory context causes skipping of exon 7 of SMN2 in spinal muscular atrophy
    Singh, NN
    Androphy, EJ
    Singh, RN
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 315 (02) : 381 - 388
  • [42] Spinal Muscular Atrophy - Is Newborn Screening Too Late for Children with Two SMN2 Copies?
    Schwartz, Oliver
    Koelbel, Heike
    Blaschek, Astrid
    Glaeser, Dieter
    Burggraf, Siegfried
    Roeschinger, Wulf
    Schara, Ulrike
    Mueller-Felber, Wolfgang
    Vill, Katharina
    JOURNAL OF NEUROMUSCULAR DISEASES, 2022, 9 (03) : 389 - 396
  • [43] Bone loss in survival motor neuron (Smn-/- SMN2) genetic mouse model of spinal muscular atrophy
    Shanmugarajan, Srinivasan
    Tsuruga, Eichi
    Swoboda, Kathryn J.
    Maria, Bernard L.
    Ries, William L.
    Reddy, Sakamuri V.
    JOURNAL OF PATHOLOGY, 2009, 219 (01): : 52 - 60
  • [44] The gene copy ratios of SMN1/SMN2 in Japanese carriers with type I spinal muscular atrophy
    Tran, TD
    Kroepfl, T
    Saito, M
    Nagura, M
    Ichiseki, H
    Kubota, M
    Toda, T
    Sakakihara, Y
    BRAIN & DEVELOPMENT, 2001, 23 (05): : 321 - 326
  • [45] High Concentration or Combined Treatment of Antisense Oligonucleotides for Spinal Muscular Atrophy Perturbed SMN2 Splicing in Patient Fibroblasts
    Wijaya, Yogik Onky Silvana
    Niba, Emma Tabe Eko
    Nishio, Hisahide
    Okamoto, Kentaro
    Awano, Hiroyuki
    Saito, Toshio
    Takeshima, Yasuhiro
    Shinohara, Masakazu
    GENES, 2022, 13 (04)
  • [46] Synthesis and biological evaluation of novel heterocyclic compounds as SMN2 promoter activators for the potential treatment of spinal muscular atrophy
    Singh, J
    Thurmond, J
    Pease, B
    Rao, M
    Palomo, M
    Pail, G
    Bedell, L
    Keyvan, M
    Mishra, R
    Zhang, J
    Onua, E
    Bjarnadottir, E
    Haraldsson, M
    Andresson, T
    Gunnseinsdottir, T
    Atlason, P
    Sigthorsson, G
    Bragason, G
    Thorsteinsdottir, M
    Gurney, M
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2756 - U2756
  • [47] Antisense oligomer mediated retention of SMN2 intron and exon 7 leads to a novel SMN transcript and increased functional SMN protein in Spinal Muscular Atrophy fibroblasts
    Mitrpant, C.
    Price, L.
    Johnsen, R. D.
    Burghes, A. H.
    Fletcher, S.
    Wilton, S. D.
    NEUROMUSCULAR DISORDERS, 2011, 21 (9-10) : 685 - 685
  • [48] Treatment of Spinal Muscular Atrophy with Antisense Morpholinos that Alter Splicing of SMN2 Good Distribution in Neonates and Adult Animals
    Burghes, Arthur
    Porensky, Paul
    Mitrpant, Charlermchai
    McGovern, Vicki
    Bevan, Adam
    Foust, Kevin
    Kaspar, Brian
    Wilton, Stephen
    NUCLEIC ACID THERAPEUTICS, 2012, 22 (06) : A10 - A11
  • [49] Natural history of distal motor neuron denervation in spinal muscular atrophy, and association of SMN2 copy number with functional outcomes
    Swoboda, KJ
    Prior, TW
    McNaught, TP
    Wride, MC
    Bromberg, MB
    NEUROMUSCULAR DISORDERS, 2004, 14 (8-9) : 597 - 597
  • [50] SMN1 and SMN2 Copy Number Distribution in 733 Clinical Cases of Carrier Screening for Spinal Muscular Atrophy
    Toledo, D.
    Hughes, E.
    Johnston, M.
    Tsongalis, G.
    Lefferts, J.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2020, 22 (05): : S16 - S16